BRIEF-Qyuns Therapeutics Says New Drug Application Of Crusekitug (Qx002n) Accepted By NMPA

Reuters03-09

BRIEF-Qyuns <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Says New Drug Application Of Crusekitug (Qx002n) Accepted By NMPA

March 9 (Reuters) - Qyuns Therapeutics Co Ltd 2509.HK:

NEW DRUG APPLICATION OF CRUSEKITUG (QX002N) FOR TREATMENT OF ACTIVE ANKYLOSING SPONDYLITIS IN ADULTS ACCEPTED BY NMPA

Further company coverage: 2509.HK

((Reuters.Briefs@thomsonreuters.com;))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2618947620?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-09 23:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618947620","market":"us","top_or_hot":-1,"title":"BRIEF-Qyuns Therapeutics Says New Drug Application Of Crusekitug (Qx002n) Accepted By NMPA","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Qyuns <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Says New Drug Application Of Crusekitug (Qx002n) Accepted By NMPA</title></head><body><p><span>March 9 (Reuters)</span><span> - </span>Qyuns Therapeutics Co Ltd <span>2509.HK</span>:</p><ul><li><p>NEW DRUG APPLICATION OF CRUSEKITUG (QX002N) FOR TREATMENT OF ACTIVE ANKYLOSING SPONDYLITIS IN ADULTS ACCEPTED BY NMPA</p></li></ul><p>Further company coverage: <span>2509.HK</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Qyuns Therapeutics Says New Drug Application Of Crusekitug (Qx002n) Accepted By NMPA</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Qyuns Therapeutics Says New Drug Application Of Crusekitug (Qx002n) Accepted By NMPA\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-09 23:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Qyuns <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Says New Drug Application Of Crusekitug (Qx002n) Accepted By NMPA</title></head><body><p><span>March 9 (Reuters)</span><span> - </span>Qyuns Therapeutics Co Ltd <span>2509.HK</span>:</p><ul><li><p>NEW DRUG APPLICATION OF CRUSEKITUG (QX002N) FOR TREATMENT OF ACTIVE ANKYLOSING SPONDYLITIS IN ADULTS ACCEPTED BY NMPA</p></li></ul><p>Further company coverage: <span>2509.HK</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02509","symbol_name":"荃信生物-B","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nFWN3ZX1BF:1","article_id":"2618947620","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2618947620","pubTimestamp":1773070401,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Qyuns Therapeutics Says New Drug Application Of Crusekitug  Accepted By NMPAMarch 9  - Qyuns Therapeutics Co Ltd 2509.HK:NEW DRUG APPLICATION OF CRUSEKITUG  FOR TREATMENT OF ACTIVE ANKYLOSING SPONDYLITIS IN ADULTS ACCEPTED BY NMPAFurther company coverage: 2509.HK ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02509":"荃信生物-B","BK1161":"生物科技"},"translate_title":"BRIEF-Qyuns Therapeutics表示Crusekitug(Qx002n)新药申请获NMPA受理","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02509":0.9},"content_text":"BRIEF-Qyuns Therapeutics Says New Drug Application Of Crusekitug (Qx002n) Accepted By NMPAMarch 9 (Reuters) - Qyuns Therapeutics Co Ltd 2509.HK:NEW DRUG APPLICATION OF CRUSEKITUG (QX002N) FOR TREATMENT OF ACTIVE ANKYLOSING SPONDYLITIS IN ADULTS ACCEPTED BY NMPAFurther company coverage: 2509.HK ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2618947620","isCrawlerRequest":true}